Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Ren-ai Xu"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Sunitinib, a newly developed multi-targeted tyrosine kinase inhibitor (TKI), has become a common therapeutic option for managing advanced renal cell carcinoma (RCC). Examining the mechanism underlying the interaction between sunit
Externí odkaz:
https://doaj.org/article/88eb762f5aae4fe0a0f8b15f1fd87a9c
Publikováno v:
Pharmaceutical Biology, Vol 62, Iss 1, Pp 874-881 (2024)
Context Almonertinib is primarily metabolized by CYP3A4, so it could interact with a variety of drugs metabolized by CYP3A4, leading to the changes of systemic exposure.Objective For the purpose of this experiment, an ultra-performance liquid chromat
Externí odkaz:
https://doaj.org/article/1a2e8cd8b4c44c0384c3efa5674d718c
Autor:
Jie Chen, Yingying Hu, Jinyu Hu, Zhize Ye, Qianmeng Lin, Jian-ping Cai, Guo-xin Hu, Ren-ai Xu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 180, Iss , Pp 117511- (2024)
The aim of this study was to investigate the catalytic activity of 26 Cytochrome P450 3A4 (CYP3A4) variants and drug interactions on imatinib metabolism in recombinant insect microsomes. This study was designed with an appropriate incubation system a
Externí odkaz:
https://doaj.org/article/3cef741ee9d0453fa4742ed7da321f06
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/e5a8107d53f445dfa877f676d916b7c5
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Ivacaftor is the first potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein approved for use alone in the treatment of cystic fibrosis (CF). Ivacaftor is primarily metabolized by CYP3A4 and therefore may interact with
Externí odkaz:
https://doaj.org/article/c55b021424b94df992213ae5b652d043
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-9 (2024)
Abstract In this study, we firstly established and verified a method by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) for the analysis of vilazodone and its metabolite M10 in rat plasma, then this method was used to ex
Externí odkaz:
https://doaj.org/article/cb108191741b450a9c52e9c30f2c2956
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Lenvatinib is a first-line therapy for the treatment of hepatocellular carcinoma (HCC), an active multi-target tyrosine kinase inhibitor (TKI). The interaction between Traditional Chinese Medicine (TCM) and chemicals has increasingly become a researc
Externí odkaz:
https://doaj.org/article/acc9e109fac54eae825de5ac96087c27
Publikováno v:
Heliyon, Vol 10, Iss 11, Pp e32187- (2024)
PAXLOVID™ (Co-packaging of Nirmatrelvir with Ritonavir) has been approved for the treatment of Coronavirus Disease 2019 (COVID-19). The goal of the experiment was to create an accurate and straightforward analytical method using ultra performance l
Externí odkaz:
https://doaj.org/article/492bf0df441d4917b6f417dba996437f
Autor:
Zhize Ye, Hailun Xia, Jinyu Hu, Ya-nan Liu, Anzhou Wang, Jian-ping Cai, Guo-xin Hu, Ren-ai Xu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116421- (2024)
Tofacitinib can effectively improve the clinical symptoms of rheumatoid arthritis (RA) patients. In this current study, a recombinant human CYP2C19 and CYP3A4 system was operated to study the effects of recombinant variants on tofacitinib metabolism.
Externí odkaz:
https://doaj.org/article/e521898341db4c25ac01509310f911d0
Publikováno v:
Pharmaceutical Biology, Vol 61, Iss 1, Pp 514-519 (2023)
AbstractContext Derazantinib—an orally bioavailable, ATP competitive, multikinase inhibitor—has strong activity against fibroblast growth factor receptors (FGFR)2, FGFR1, and FGFR3 kinases. It has preliminary antitumor activity in patients with u
Externí odkaz:
https://doaj.org/article/f3a7403c8b3a400db013d1d708ef9041